Ophthalmology Therapeutics in Major Developed Markets to 2019 – New Drug Approvals and Promising Pipeline to Trigger Shift in Treatment Paradigm to Combination Therapies...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 9
2 Ophthalmology Therapeutics in Major Markets – Introduction 10
2.1 Dry Eye Syndrome 10
2.1.1 Classification 10
2.1.2 Symptoms 10
2.1.3 Etiology 10
2.1.4 Pathophysiology 11
2.1.5 Diagnosis 12
2.1.6 Epidemiology 13
2.1.7 Prognosis 14
2.1.8 Treatment Options 14
2.2 Glaucoma 15
2.2.1 Classification 15
2.2.2 Symptoms 16
2.2.3 Etiology 16
2.2.4 Pathophysiology 17
2.2.5 Diagnosis 17
2.2.6 Epidemiology 18
2.2.7 Prognosis 19
2.2.8 Treatment Options 19
3 Ophthalmology Therapeutics in Major Markets – Marketed Products (Global) 21
3.1 Dry Eye Syndrome 21
3.2 Glaucoma 21
3.3 Key Marketed Products 22
3.3.1 Restasis 22
3.3.2 Systane 23
3.3.3 Diquas 24
3.3.4 Mucosta 25
3.3.5 Hyalein 26
3.3.6 Lumigan 27
3.3.7 Alphagan/Alphagan P 28
3.3.8 Simbrinza 29
4 Ophthalmology Therapeutics in Major Markets – Pipeline Analysis 30
4.1 Dry Eye Syndrome Pipeline 30
4.1.1 Overall Pipeline 30
4.1.2 Pipeline Analysis by Molecule Type 32
4.1.3 Pipeline Analysis by Mechanism of Action 34
4.2 Glaucoma Pipeline 36
4.2.1 Overall Pipeline 36
4.2.2 Pipeline Analysis by Molecule Type 38
4.2.3 Pipeline Analysis by Mechanism of Action 39
4.3 Promising Drug Candidates in the Pipeline 41
4.3.1 CF-101 41
4.3.2 MIM-D3 41
4.3.3 SAR-1118 41
4.3.4 DE-111 42
5 Ophthalmology Therapeutics in Major Markets – Market Forecast to 2019 43
5.1 Major Markets 43
5.1.1 Treatment Usage Patterns 43
5.1.2 Annual Cost of Therapy 43
5.1.3 Market Size 43
5.2 The US 45
5.2.1 Treatment Usage Patterns 45
5.2.2 Annual Cost of Therapy 45
5.2.3 Market Size 45
5.3 Top Five European Countries 47
5.3.1 Treatment Usage Patterns 47
5.3.2 Annual Cost of Therapy 47
5.3.3 Market Size 47
5.4 Canada 49
5.4.1 Treatment Usage Patterns 49
5.4.2 Annual Cost of Therapy 49
5.4.3 Market Size 49
5.5 Japan 51
5.5.1 Treatment Usage Patterns 51
5.5.2 Annual Cost of Therapy 51
5.5.3 Market Size 51
5.6 Drivers and Barriers 53
5.6.1 Drivers 53
5.6.2 Barriers 53
6 Ophthalmology Therapeutics in Major Markets – Deals and Strategic Consolidations (Global) 55
6.1 Deals Analysis 55
6.2 Major Co-Development Deals 57
6.2.1 NicOx Signs Research Agreement with Pfizer 58
6.2.2 Acucela Enters into Co-development Agreement with Otsuka Pharma for Rebamipide 58
6.2.3 Akorn Enters into Agreement with Azad Pharma 58
6.3 Major Licensing Deals 59
6.3.1 NicOx Enters into Worldwide Licensing Agreement with Bausch & Lomb 60
6.3.2 Quark Pharma Amends Licensing Agreement with Pfizer for PF-655 60
6.3.3 Asterand Enters into Licensing Agreement with Allergan 60
7 Ophthalmology Therapeutics in Major Markets – Appendix 61
7.1 All Pipeline Drugs by Phase 61
7.1.1 Discovery 61
7.1.2 Preclinical 61
7.1.3 IND/CTA-filed 63
7.1.4 Phase I 63
7.1.5 Phase II 64
7.1.6 Phase III 65
7.1.7 Pre-registration 65
7.1.8 Undisclosed 66
7.2 Market Forecasts to 2019 66
7.2.1 Major Markets 66
7.2.2 The US 67
7.2.3 The UK 67
7.2.4 France 68
7.2.5 Germany 69
7.2.6 Italy 69
7.2.7 Spain 70
7.2.8 Canada 71
7.2.9 Japan 71
7.3 Market Definitions 72
7.4 Abbreviations 72
7.5 Sources 74
7.6 Research Methodology 75
7.6.1 Coverage 76
7.6.2 Secondary Research 76
7.6.3 Primary Research 76
7.6.4 Therapeutic Landscape 77
7.6.5 Geographical Landscape 80
7.6.6 Pipeline Analysis 80
7.7 Expert Panel Validation 80
7.8 Contact Us 80
7.9 Disclaimer 80